SecBot SecBot
3 ·Filed Nov 12, 2026

NIKI

Niki BioSolutions, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed5d 6h ago SEC0001213900-26-118618
Form 3: initial insider ownership statement
Actionable Insight • Neutral

Routine CFO onboarding filing. No immediate trading signal. Monitor for future equity grants or capital raises tied to the $5M cumulative capital vesting milestone.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.70
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.94%
T+1 · $1.65
Vs SPY
−2.58%
α at T+1
Next horizon
T+5
tomorrow
  1. T+0 · Nov 12 $1.70entry
  2. T+1 · 4d ago −2.94%α −2.58% · $1.65
  3. T+3 · todayOpen
  4. T+5 · tomorrow Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Thomas John Freeburg filed a Form 3 initial statement of beneficial ownership after becoming CFO of Niki BioSolutions, Inc. The filing discloses stock options for 75,000 shares at $8.83, with vesting tied to milestones including an annual report, quarterly installments, capital raises, and change of control. This is a routine insider filing with no material financial impact.

Key Facts

  • Thomas John Freeburg appointed CFO of Niki BioSolutions, Inc.
  • Granted options to purchase 75,000 shares at $8.83 per share on September 1, 2026.
  • Options vest in tranches: 15,000 upon first full Annual Report filing; 20,000 over eight quarters; 15,000 upon $5M cumulative capital; 25,000 upon change of control.
  • All unvested options accelerate upon change of control.
  • Form 3 filed on 2026-11-12, reporting period start 2026-10-09.

Financial Impact

Options for 75,000 shares at $8.83, representing approximately 0.75% of shares outstanding based on $5M market cap and $8.83 option price (implied ~566,000 shares outstanding). No immediate cash impact.

dilution

Risk Factors

  • Options vesting milestones may create future dilution if capital raises occur.
  • No financial data in filing to assess company performance.

Market Snapshot

Exchange
Nasdaq
Sector
Measuring & Controlling Devices, NEC
Analyst Consensus
88% bullish (8 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001213900-26-118618
Document: 0001213900-26-118618-index.html0001213900-26-118618
Document: 0001213900-26-118618.txt0001213900-26-118618

Track record

8 reports on NIKI

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +62.57% at T+20 after the Oct 2, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 17, 2026today NT 10-Q Neutral 5/10 Entry $1.71 Now $1.50 −12.28% settles Dec 17
  2. Nov 12, 20265d ago 3 Neutral 2/10 Viewing Entry $1.70 Now $1.50 −11.76% settles Dec 11
  3. Oct 13, 20265w ago EFFECT Bearish 5/10 Entry $2.63 to $1.61 Now $1.50 +42.86% ▲ +38.67% +35.06% vs SPY
  4. Oct 2, 20266w ago S-3/A Bearish 6/10 Entry $4.73 to $1.77 Now $1.50 +68.28% ▲ +62.57% +60.10% vs SPY
  5. Sep 25, 20267w ago Press Release Neutral 2/10 Entry $4.76 to $1.83 Now $1.50 −68.49% ▼ −61.55% −60.08% vs SPY
  6. Sep 18, 20268w ago S-3/A Bearish 5/10 Entry $4.97 to $2.08 Now $1.50 +69.82% ▲ +58.15% +57.24% vs SPY
  7. Aug 27, 202611w ago S-3 Bearish 5/10 Entry $6.90 to $4.70 Now $1.50 +78.26% ▲ +31.88% +32.14% vs SPY
  8. Aug 7, 202614w ago 8-K Neutral 3/10 Entry $8.62 to $6.28 Now $1.50 −82.60% ▼ −27.15% −26.23% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026